Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?
Table 3
Multivariate model for competing risk analysis using Fine and Gray’s test [20] of significance of prostate cancer specific survival.
Variable
Univariate analysis
Multivariate analysisa
Hazard ratio
95% confidence interval
value
10 yr PCSS %
Hazard ratio
95% confidence interval
value
Statin (yes versus no)
0.656
0.478–0.898
0.0086
94.1 versus 91.1
0.769
0.548–1.08
NS
ASA (yes versus no)
0.728
0.537–0.985
0.040
93.4 versus 91.3
0.911
0.648–1.282
NS
Age
0.986
0.968–1.005
0.14
—
0.988
0.972–1.005
NS
Year of treatment (≥2004 versus ≤2003)
1.176
0.924–1.498
0.19
95.9 versus 98.5b
1.172
0.897–1.530
NS
Radiation dose
1.000
0.999–1.000
0.13
—
1.000
0.999–1.000
NS
ADTc (yes versus no)
1.789
1.418–2.500
0.0003
90.5 versus 94.5
0.710
0.481–1.049
0.085
iPSAd
2.764
1.988–3.843
<0.0001
—
1.59
1.13–2.24
0.0085
stage
97.1
(2 versus 1)
2.419
1.532–3.820
0.0002
93.5
2.10
1.33–3.33
0.0015
(3 versus 1)
5.916
3.766–9.924
<0.0001
85.6
3.83
2.41–6.08
<0.0001
(4 versus 1)
18.682
10.17–34.31
<0.0001
64.1
11.38
6.11–21.21
<0.0001
Charlson index
90.9
(1 versus 0)
0.749
0.563–0.998
0.048
92.8
0.76
0.57–1.02
0.072
(≥2 versus 0)
0.495
0.298–0.823
0.0067
95.1
0.53
0.32–0.87
0.013
Gleason score
96.7
(7 versus ≤6)
2.611
1.823–3.739
<0.0001
92.0
1.94
1.34–2.82
0.005
(≥8 versus ≤6)
5.718
3.987–8.202
<0.0001
83.2
3.21
2.16–4.78
<0.0001
NS: not significant ().
aVariables with in univariate analysis were included in model for multivariate analysis.
bYear of treatment is 5-year survival.
ciPSA: initial pretreatment PSA.
dADT: androgen deprivation therapy.
